DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults. Acne is associated with low an effective acne treatment that also calms the user's skin and self-esteem and social inhibition in those that suffer from does not have a drying effect. acne especially if it is particularly severe. Several factors may 0006 Even good acne treatments may not be able to pre contribute to the development of acne. The primary problem Ventall breakouts of acne. Treatments, such as masks, that are being the abnormal flaking of cells inside the hair follicle that developed specifically to target an acne breakout or appear leads to the formation of a plug. The plug can enlarge and ance of a blemish tend to leave the skin drier and are not even rupture the hair follicle. A ruptured hair follicle spills its always effective. Therefore, it would be beneficial to provide contents of oil and debris into the skin where it leads to an acne treatment that could target a specific breakout or Swelling and causes redness (inflammation). Naturally-oc blemish that does not have a drying effect on the user's skin. curring bacteria known as Propionibacterium acnes may also 0007 Another known treatment of acne and acne break be responsible for causing acne. These bacteria produce Sub outs is cortisone injection therapy. Cortisone injection stances that cause redness and irritation (inflammation) and therapy may be very useful as a method of treating acne; also make enzymes that dissolve the sebum (oil from oil however these shots can be painful and do not get at the root glands in the skin) and thereby create irritating Substances cause of the acne. Cortisone injection therapy is also not that can make the inflammation worse. Suggested for long-term treatment. Therefore, it would be 0002 Certain hormones called androgens can be an addi beneficial to provide a topical acne treatment that could spe tional factor in causing acne. Androgens are male hormones cifically target a breakout or blemish but could also be used that are present in both men and women and both enlarge the for long-term treatment of acne. sebaceous glands in the skin as well as cause glands to increase sebum production. The increased sebum leads to SUMMARY OF THE INVENTION plug formation and serves as more “food for the bacteria. Androgens Surge at puberty which contributes to the devel 0008. The present invention generally relates to topical opment of acne in teenagers and young adults. skin care compositions and methods for treatment of acne. 0003 Hair follicles exist on virtually all skin except for the The skin care composition hereof has the unique ability to palms of the hands and soles of the feet. Inside the follicle, the treat acne without drying out the user's skin. In particular, a hair extends up from the deep layers of the skin and comes out topical skin care composition is provided that includes a base, of a pore. Near the Surface, the oil gland (sebaceous gland) an antibacterial agent, at least one anti-inflammatory agent enters the hair follicle where it empties sebum at a relatively and at least one antioxidant. In one non-limiting illustration, constant rate. The sebum lubricates the skin and provides a the composition contains benzoyl peroxide, evodia rutae protective barrier to prevent drying. Skin on the face, chest, carpa, boswellia serrata, quercetin, oleanolic acid, and tea and back has an especially large number of sebaceous glands. eXtractS. These are the areas where acne is most likely to occur. 0004. There are two major types of acne lesions: nonin DETAILED DESCRIPTION OF THE INVENTION flammatory and inflammatory. Noninflammatory acne lesions include blackheads (open comedones) and white 0009. There is provided herein a topical skin care compo heads (closed comedones). Open and closed comedones sition that treats acne without drying out the user's skin. The along with papules and pustules are commonly referred to as skin care composition hereof generally includes a base, an papulopustular acne which is a form of inflammatory acne. antibacterial agent, at least one anti-inflammatory agent, and Nodular acne is the most severe form of inflammatory acne. at least one antioxidant. It will be appreciated by those skilled Open comedones result from the enlargement and dilation of in the art that some agents disclosed throughout may have two a plug that forms from oil and flakes of skin inside the hair or more properties; for example, benzoyl peroxide can act as follicle. A closed comedone forms if the hair follicle pore both an antibacterial agent as well as an anti-inflammatory remains closed. Inflammatory acne lesions consist of red agent. blemishes, pimples (papules, pustules), and larger, deeper, 0010. In one embodiment, the skin care composition Swollen, and tender lesions (nodules). Papules are closed includes an effective amount of a base. In certain embodi comedones that have become red, Swollen, and inflamed. ments, the base is present in an amount of from about 1.0 to Pustules are closed comedones that become inflamed and 100.0 w/w % of the composition, more preferably from about begin to rupture into the skin forming pustular heads of vari 10.0 to 95.0 w/w %, and most preferably from about 20 to 95 ous sizes. Nodules represent large, tender, Swollen acne w/w %. Preferred bases include, but are not limited to, soaps, lesions that have become intensely inflamed and rupture washes, lotions, creams, gels, masks, ointments, Solutions, under the skin. If left untreated, these nodules can produce scrubs, microdermabrasion creams, serums, strips, patches, deep Scarring. and combinations thereof. 0005. There are a variety of topical therapies available to 0011. In one embodiment, the skin care composition may treat and prevent acne. Topical retinoids Such as tretinoin or also include an effective amount of an antibacterial agent. In adapalene are effective for treating comedonal acne. Inflam certain embodiments, the antibacterial agent is present in an matory lesions benefit from treatment with benzoyl peroxide, amount of from about 0.001 to 20.0 w/w % of the composi aZelaic acid or topical antibiotics. Benzoyl peroxide, in over tion, more preferably from about 0.15 to 10.0 w/w %, and the-counter and prescription formulations, has been a main most preferably about 5 w/w %. In certain other embodi US 2010/0221 245 A1 Sep. 2, 2010 ments, the antibacterial agent is benzoyl peroxide and is pref reduces glycosaminoglycan degradation and therefore long erably about 5 w/w % of the skin care composition. term use of boswellia does not lead to irritation and has a 0012. In addition to benzoyl peroxide, other antibacterial Soothing effect on human skin. Quercetin is a flavonoid and agents Suitable for use in the present invention include, but are has antioxidant and anti-inflammnatory activities. not limited to, bacitracin, polymyxin B, neomycin, mupiro 0014. Other suitable anti-inflammatory agents for use in cin, hydrastine, aminopropanesulphonic acid, acetohydrox the present invention include, but are not limited to, benzoyl amic acid, actinonin, actinospectacin, aklavin hydrochloride, peroxide, benzoyl peroxide and clindamycin combinations, alexidine hydrochloride, amikacin Sulfate, amoxicillin, ampi clindamycin, erythromycin, tetracycline, alpha hydroxyl cillin Sodium, azithromycin, azlocillin Sodium, bacampicillin acid, Salicylic acid, filipendula and meadowsweet, curled hydrochloride, bacitracin, becanamycin, butirosin A, cam dock (rumex crispus), licorice extract, acetaminophen, ace phor, cannabidiol, capreomycin Sulfate, carbenicillin diso tylsalicyclic acid, acetic acid, Zinc oxide, Zinc sulfate, hydro dium, cefadroxil, cefazolin sodium, cefotaxime Sodium, cortisone, prednisone, Solumedrol, prednisolone, white tea cephalosporin Sodium, cephalothin Sodium, cephapirin extract, green tea extract, caffeine, tannis, isatsis indigotica Sodium, cephradine sodium, chloramphenicol hemisucci root extract, menthol, 18alpha-glcyrrhetinic acid, naproxen, nate, chloramphenicol,
Load more

Recommended publications
  • Evodiae Fructus on Targeted Distribution of Berberine in Rats
    Int J Clin Exp Med 2018;11(8):7701-7709 www.ijcem.com /ISSN:1940-5901/IJCEM0073795 Original Article Effects of Evodiae Fructus on targeted distribution of berberine in rats Rui-Feng Liang, Wen-Jing Ge, Hui-Sen Wang, She-Feng Zhang, Xue-Xia Zhang, Geng-Sheng Li Institute of Chinese Materia Medica, Henan Provincial Academy of Traditional Chinese Medicine, Zhengzhou 450003, Henan Province, China Received September 20, 2017; Accepted May 24, 2018; Epub August 15, 2018; Published August 30, 2018 Abstract: According to Traditional Chinese Medicine (TCM) theories, Evodiae Fructus (EF) was considered as a meridian guiding drug (MGD) in Zuojin Pill and could enhance the effectiveness of prescription. However, the sci- entific evidence for this effect is still unclear. In this study, the meridian guiding mechanism of EF was investigated. Rats were randomly divided into four groups, control group (water), low dose of EF (250 mg/kg), medium dose of EF (500 mg/kg) and high dose of EF (1000 mg/kg). Water or EF was given to the rats by intragastric administra- tion for 7 days. After the last administration, berberine (80 mg/kg) was administered to rats by gavage. Then the blood and tissues of interest were collected at predetermined time points. Concentrations of berberine in different tissues were analysed by ultra-performance liquid-chromatography tandem mass spectrometry (UPLC-MS/MS) and the target parameters including relative targeting efficiency (RTE), relative uptake efficiency (RUE) and maximum relative concentration (RCmax) were calculated. Compared with control group, various doses of EF could improve the targeting efficiency of berberine in liver.
    [Show full text]
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • From Inverse Agonism to 'Paradoxical Pharmacology' Richard A
    International Congress Series 1249 (2003) 27-37 From inverse agonism to 'Paradoxical Pharmacology' Richard A. Bond*, Kenda L.J. Evans, Zsirzsanna Callaerts-Vegh Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 521 Science and Research Bldg 2, 4800 Caltioun, Houston, TX 77204-5037, USA Received 16 April 2003; accepted 16 April 2003 Abstract The constitutive or spontaneous activity of G protein-coupled receptors (GPCRs) and compounds acting as inverse agonists is a recent but well-established phenomenon. Dozens of receptor subtypes for numerous neurotransmitters and hormones have been shown to posses this property. However, do to the apparently low percentage of receptors in the spontaneously active state, the physiologic relevance of these findings remains questionable. The possibility that the reciprocal nature of the effects of agonists and inverse agonists may extend to cellular signaling is discussed, and that this may account for the beneficial effects of certain p-adrenoceptor inverse agonists in the treatment of heart failure. © 2003 Elsevier Science B.V. All rights reserved. Keywords. Inverse agonism; GPCR; Paradoxical pharmacology 1. Brief history of inverse agonism at G protein-coupled receptors For approximately three-quarters of a century, ligands that interacted with G protein- coupled receptors (GPCRs) were classified either as agonists or antagonists. Receptors were thought to exist in a single quiescent state that could only induce cellular signaling upon agonist binding to the receptor to produce an activated state of the receptor. In this model, antagonists had no cellular signaling ability on their own, but did bind to the receptor and prevented agonists from being able to bind and activate the receptor.
    [Show full text]
  • Lymphoid Organs of Neonatal and Adult Mice Preferentially Produce Active Glucocorticoids from Metabolites, Not Precursors ⇑ Matthew D
    Brain, Behavior, and Immunity 57 (2016) 271–281 Contents lists available at ScienceDirect Brain, Behavior, and Immunity journal homepage: www.elsevier.com/locate/ybrbi Full-length Article Lymphoid organs of neonatal and adult mice preferentially produce active glucocorticoids from metabolites, not precursors ⇑ Matthew D. Taves a,b, , Adam W. Plumb c, Anastasia M. Korol a, Jessica Grace Van Der Gugten d, Daniel T. Holmes d, Ninan Abraham b,c,1, Kiran K. Soma a,b,e,1 a Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver V6T 1Z4, Canada b Department of Zoology, University of British Columbia, 4200-6270 University Blvd, Vancouver V6T 1Z4, Canada c Department of Microbiology and Immunology, University of British Columbia, 1365-2350 Health Sciences Mall, Vancouver V6T 1Z3, Canada d Department of Laboratory Medicine, St Paul’s Hospital, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada e Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada article info abstract Article history: Glucocorticoids (GCs) are circulating adrenal steroid hormones that coordinate physiology, especially the Received 4 March 2016 counter-regulatory response to stressors. While systemic GCs are often considered immunosuppressive, Received in revised form 22 April 2016 GCs in the thymus play a critical role in antigen-specific immunity by ensuring the selection of competent Accepted 7 May 2016 T cells. Elevated thymus-specific GC levels are thought to occur by local synthesis, but the mechanism of Available online 7 May 2016 such tissue-specific GC production remains unknown. Here, we found metyrapone-blockable GC produc- tion in neonatal and adult bone marrow, spleen, and thymus of C57BL/6 mice.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Rhinitis - Allergic (1 of 15)
    Rhinitis - Allergic (1 of 15) 1 Patient presents w/ signs & symptoms of rhinitis 2 • Consider other classifi cations of rhinitis DIAGNOSIS No - Please see Rhinitis Is allergic rhinitis - Nonallergic disease confi rmed? management chart Yes 3 ASSESS DURATION & SEVERITY OF ALLERGIC RHINITIS A Non-pharmacological therapy • Allergen avoidance • Patient education VAS <5 VAS ≥5 B Pharmacological therapy B Pharmacological therapy • Antihistamines (oral/nasal), &/or • Corticosteroids (nasal), w/ or without • Corticosteroids (nasal), or • Antihistamines (nasal), or • Cromone (nasal), or • LTRA • Leukotriene receptor antagonists (LTRA)MIMS TREATMENT © See next page Specifi cally for patients w/ asthma Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B167 © MIMS Pediatrics 2020 Rhinitis - Allergic (2 of 15) Previously treated symptomatic Previously treated symptomatic patient (VAS <5) on antihistamines patient (VAS ≥5) on intensifi ed (oral/nasal) &/or corticosteroids (nasal) therapy w/ corticosteroids (nasal) w/ or without antihistamines (nasal) Intermittent Persistent symptoms, symptoms or without allergen w/ allergen exposure exposure B Pharmacological therapy B Pharmacological therapy • Step down or discontinue therapy • Continue or step up therapy Untreated REASSESS DISEASE SEVERITY VAS symptomatic patient DAILY UP TO DAY 3 (VAS <5 or ≥5) 4 CONTINUE Yes THERAPY & STEP EVALUATION VAS <5 DOWN THERAPY1 Improvement of symptoms? No VAS ≥5 B Pharmacological therapy • Step-up therapy REASSESS DISEASE SEVERITY MIMSVAS DAILY UP TO DAY 7 4 Yes EVALUATION VAS <5 Improvement of symptoms? No TREATMENT © VAS ≥5 See next page Continue therapy if symptomatic; consider step-down or discontinuation of therapy if symptoms subside Not all products are available or approved for above use in all countries.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]